If you live with hidradenitis suppurativa (HS) or care for someone who does, you know how draining it can be—not just physically, but emotionally. The pain, scarring, flare-ups, and unpredictability affect everything from how you dress to how you move through your day.
That’s why news of a promising new oral treatment—povorcitinib—is worth paying attention to. It’s currently being tested in Phase 3 trials, and its early results suggest it could offer relief in ways that older therapies can’t. Below, I’ll walk you through what this trial is, who it might be for, what you’d have to do if you join, and what benefits and questions to keep in mind.
HS has long presented a difficult therapeutic challenge. Many treatments require injections or biologic infusions; some don’t fully suppress flare-ups; side effects limit long-term use; and access is uneven across populations.
Povorcitinib is different because:
It’s oral. That means no IV treatments or injections—just a pill, which could make it easier for people who struggle with frequent clinic visits.
In its Phase 3 STOP-HS trials (STOP-HS1 and STOP-HS2), it showed statistically significant improvements for HS patients at both 45 mg and 75 mg doses, compared to placebo. PharmExec+3Dermatology Times+3The Dermatology Digest+3
By 24 weeks, nearly 60% of patients treated with povorcitinib achieved a HiSCR50 (≥ 50% reduction in abscess + inflammatory nodule count, without worsening abscesses or draining tunnels). Investing News Network (INN)+2Dermatology Times+2
It also showed improvements in skin pain, flare reduction, and tunnel resolution (i.e., draining tunnels) in many participants. The Dermatology Digest+1
Safety signals were in line with expectations; serious adverse events were relatively low, and no deaths or major cardiovascular events occurred over the 24-week observation period. The Dermatology Digest+2HCPLive+2
In short, povorcitinib may offer a more flexible, less invasive treatment path for HS, with real promise for improving daily life.
Here’s a rough sketch (not an official screener) of who might qualify based on trial designs:
Adults 18 years or older Incyte Clinical Trials+2Incyte Clinical Trials+2
Diagnosed with moderate to severe HS, with disease activity for at least 3 months prior to screening The Dermatology Digest+3Incyte Clinical Trials+3Dermatology Times+3
Presence of abscesses and inflammatory nodules (AN count ≥ 5), in two or more distinct anatomical areas (for example, both armpits, or groin plus under breast) PharmExec+3Incyte Clinical Trials+3Incyte Clinical Trials+3
Those who have had inadequate response to at least one conventional systemic therapy (like oral antibiotics or a biologic) or could not tolerate standard options Bioworld+3Incyte Clinical Trials+3Incyte Clinical Trials+3
Exclusion criteria may include some cardiovascular risks, active infections, hematologic issues, or other conditions—these vary per trial site and protocol. Incyte Clinical Trials+2Incyte Clinical Trials+2
If you believe you might qualify, the next step is contacting a trial site, reviewing the informed consent form, and discussing it with your dermatologist or trusted healthcare provider.
If you enroll in a povorcitinib trial, here’s what you can typically expect (though details vary by site and protocol):
| Aspect | What You’d Likely Do |
|---|---|
| Treatment mode | Daily oral pill (e.g., 45 mg or 75 mg) The Dermatology Digest+3Dermatology Times+3The Dermatology Digest+3 |
| Duration & schedule | First 12 weeks often blinded (with placebo vs drug), then extension phases; many sites follow participants through 24 weeks and beyond The Dermatology Digest+3Incyte Clinical Trials+3ClinicalTrials.gov+3 |
| Clinic visits & exams | Baseline screening (labs, imaging, documentation), periodic skin exams, safety labs, symptom questionnaires (“patient-reported outcomes”) ClinicalTrials.gov+4Incyte Clinical Trials+4Incyte Clinical Trials+4 |
| Safety monitoring | Adverse event tracking, possible extra visits if issues arise, criteria to pause or stop treatment if necessary The Dermatology Digest+3The Dermatology Digest+3HCPLive+3 |
| Time commitment | Expect several in-person visits (often every few weeks or monthly), plus your daily pill regimen and possibly diaries or surveys between visits |
| Support (potential) | Some trial sites may offer stipends, reimbursement for travel or parking, lodging, or compensation—but always confirm locally with the site coordinator |
The trial is generally free in the sense that the investigational drug and required tests (per protocol) are covered by the sponsor. But incidental costs (travel, meals, time off work) may or may not be compensated, depending on the location. Always ask.
Potential access to a cutting-edge treatment that isn’t yet available commercially
Free medical monitoring, research labs & exams, which can sometimes catch issues early
Compensation, reimbursement, or support (travel, lodging) in many trials
Being part of something bigger: by participating, you help pave the way for future HS therapies that may benefit others in your community
As with all trials, side effects are possible. Even if previous data look clean, unknown reactions can occur.
You may have to commit time (travel, visits). That’s harder in jobs/families with limited flexibility.
The drug being tested may or may not work for you; there’s no guarantee.
You’ll sign an informed consent—so you’ll know the known risks upfront.
You can withdraw at any time if you feel it’s not right for you.
Talk to your dermatologist or primary care provider. Bring up povorcitinib (or the STOP-HS trial) and ask whether this is a trial you could qualify for.
Search trial registries.
ClinicalTrials.gov — search “hidradenitis suppurativa povorcitinib” or trial IDs NCT05620823 / NCT05620836 PharmExec+3Incyte Clinical Trials+3Incyte Clinical Trials+3
Incyte’s clinical trials site, or the official STOP-HS trial pages, Incyte Clinical Trials+1
Contact trial sites directly. Use the contact information on ClinicalTrials.gov or the Incyte trial pages. Ask to be pre-screened.
Request the Informed Consent Document. Review it carefully. Ask questions.
If accepted, commit to keeping appointments, tracking symptoms, and staying in communication with the research team.
HS is often underdiagnosed and undertreated, especially in underserved communities. Black patients, women, and other marginalized groups have historically been underrepresented in clinical research. When we show up, our voices, our bodies, and our experiences get included in the science.
You’re not signing up just for yourself. You’re helping build data for future patients who look like you. You’re helping shape treatments that respond to your skin, your pain, your life.
Even if povorcitinib isn’t a perfect fit for you, trial participation inserts your story into the next chapter of HS care—where better, more effective, more inclusive treatment is possible.
By subscribing, you consent to receive emails from BlackDoctor.com. You may unsubscribe at any time. Privacy Policy & Terms of Service.
